Advertising

Reliq Health Techniques

RHT-X

Analysis and Opinions about RHT-X

Signal
Opinion
Expert
Chart
TOP PICK
TOP PICK
September 2, 2021
Remote monitoring of chronic disease. Real-time reporting to doctors. Slowed by Covid. Cashflow positive this quarter. Subscription model. Solid growth trajectory. CEO has a lot of skin in the game. No dividend.
Show full opinionHide full opinion
Remote monitoring of chronic disease. Real-time reporting to doctors. Slowed by Covid. Cashflow positive this quarter. Subscription model. Solid growth trajectory. CEO has a lot of skin in the game. No dividend.
BUY
BUY
April 12, 2021
It has a great product and is coming back after stubbing its toe three years ago. The market now likes it. Good opportunity for the company going forward, because telemedicine is in vogue and the US government will pay for results-based compensation.
Show full opinionHide full opinion
It has a great product and is coming back after stubbing its toe three years ago. The market now likes it. Good opportunity for the company going forward, because telemedicine is in vogue and the US government will pay for results-based compensation.
Robert McWhirter
Price
$0.580
Owned
Unknown
WATCH
WATCH
December 9, 2019
They said they will be cash flow positive moving into 2020. If they have the growth rate they are projecting, then you will see the stock start to move again. Right now it is in the penalty box.
Show full opinionHide full opinion
They said they will be cash flow positive moving into 2020. If they have the growth rate they are projecting, then you will see the stock start to move again. Right now it is in the penalty box.
DON'T BUY
DON'T BUY
November 25, 2019
It hasn't done well due to accounting issues. He recommnded it before, but hasn't gone back to this. Too many compliance issues here. He's heard that revenues and contracts look positive. No, he's been burned and avoids this.
Show full opinionHide full opinion
It hasn't done well due to accounting issues. He recommnded it before, but hasn't gone back to this. Too many compliance issues here. He's heard that revenues and contracts look positive. No, he's been burned and avoids this.
Peter Imhof
Price
$0.570
Owned
No
DON'T BUY
DON'T BUY
September 25, 2019
A former top pick. They have long-term potential, but need to show they can add clients and be cash-flow positive. The stock is starting to recover.
Show full opinionHide full opinion
A former top pick. They have long-term potential, but need to show they can add clients and be cash-flow positive. The stock is starting to recover.
DON'T BUY
DON'T BUY
June 13, 2019
He exited this story and is not going back to it because of structural problems. But it has gone up since then.
Show full opinionHide full opinion
He exited this story and is not going back to it because of structural problems. But it has gone up since then.
Peter Imhof
Price
$0.285
Owned
No
WATCH
WATCH
January 30, 2019
It was a past Top Pick, but he is not in it today. back in 2018 they were adding patients and there were high expectations on growing cash flow. Then they had cash flow recognition issue on the accounting side as patients were slower to sign on than expected. If they can deal with those issues it will become a cash flow machine. They have cash on hand to help grow the company.
Show full opinionHide full opinion
It was a past Top Pick, but he is not in it today. back in 2018 they were adding patients and there were high expectations on growing cash flow. Then they had cash flow recognition issue on the accounting side as patients were slower to sign on than expected. If they can deal with those issues it will become a cash flow machine. They have cash on hand to help grow the company.
PAST TOP PICK
PAST TOP PICK
January 23, 2019
(A Top Pick Dec 21/17, Down 76%) They exited this position. He entered around $0.80 and exited a large position around $1.80. The company faced a down turn in October after they had revenue recognition issues and contracts that had been signed and that is when they exited. He needs to see management prove up revenues before re-entering.
Show full opinionHide full opinion
(A Top Pick Dec 21/17, Down 76%) They exited this position. He entered around $0.80 and exited a large position around $1.80. The company faced a down turn in October after they had revenue recognition issues and contracts that had been signed and that is when they exited. He needs to see management prove up revenues before re-entering.
Peter Imhof
Price
$0.330
Owned
No
PAST TOP PICK
PAST TOP PICK
December 12, 2018
(A Top Pick Nov 08/17, Down 54%) He sold out as high as $2.35 and then again at $0.85. Having stops with these small companies is important. They simply have not been able to execute as they promised. Now they have revenue recognition issues with their reporting.
Show full opinionHide full opinion
(A Top Pick Nov 08/17, Down 54%) He sold out as high as $2.35 and then again at $0.85. Having stops with these small companies is important. They simply have not been able to execute as they promised. Now they have revenue recognition issues with their reporting.
SELL
SELL
October 26, 2018

He recommended it two years ago. Recently they warned that revenues would be delayed. They have governance issues too. He sold his shares. He saw too many red flags and expects lawsuits against them. He feels bad, because he recommended this stock. He has no confidence in management. Sometimes you have to take your lumps.

Show full opinionHide full opinion

He recommended it two years ago. Recently they warned that revenues would be delayed. They have governance issues too. He sold his shares. He saw too many red flags and expects lawsuits against them. He feels bad, because he recommended this stock. He has no confidence in management. Sometimes you have to take your lumps.

Peter Imhof
Price
$0.480
Owned
No
DON'T BUY
DON'T BUY
October 17, 2018

Unfortunately their technology has been slowing getting out into the market and now they have a receivables collection financial issue. It does not look good, he says.

Show full opinionHide full opinion

Unfortunately their technology has been slowing getting out into the market and now they have a receivables collection financial issue. It does not look good, he says.

PAST TOP PICK
PAST TOP PICK
October 4, 2018

(A Top Pick Oct 12/17, Up 175%) It is advanced monitoring in the home. There are delays in their hardware. The market is starting to question if they will miss their guidance for the end of the year.

Show full opinionHide full opinion

(A Top Pick Oct 12/17, Up 175%) It is advanced monitoring in the home. There are delays in their hardware. The market is starting to question if they will miss their guidance for the end of the year.

COMMENT
COMMENT
September 13, 2018

A high-risk company in an interesting space. Healthcare providers and governments want to keep people out of hospitals, so Reliq benefits. Reliq's technology can monitor people recovering from home. They're signing contracts in Texas. They target $26 million annual recurring revenue. They've had a few product missteps, so they need to deliver that $26 million target. They're also in the process of signing contracts in Canada and Australia. This could be a big business one day, but there's a lot of risk here.

Show full opinionHide full opinion

A high-risk company in an interesting space. Healthcare providers and governments want to keep people out of hospitals, so Reliq benefits. Reliq's technology can monitor people recovering from home. They're signing contracts in Texas. They target $26 million annual recurring revenue. They've had a few product missteps, so they need to deliver that $26 million target. They're also in the process of signing contracts in Canada and Australia. This could be a big business one day, but there's a lot of risk here.

Ryan Modesto
Price
$1.210
Owned
Unknown
BUY
BUY
August 10, 2018

This is a tele-health business that provides technology to provide alerts on patient status. It is a good risk-reward at these levels. They just announced another pilot project with doctors in Australia. He sees great growth opportunity in the future.

Show full opinionHide full opinion

This is a tele-health business that provides technology to provide alerts on patient status. It is a good risk-reward at these levels. They just announced another pilot project with doctors in Australia. He sees great growth opportunity in the future.

Mike Archibald
Price
$1.590
Owned
Yes
BUY
BUY
July 25, 2018

They started to do Beta testing on this new software, then starting onboarding clients. The stock had ran up, then recently pulled back. Then, they ran into delays onboarding clients due to a hardware issue They should be back on track now. This will generate huge cash flow as they add subscribers; it will continue to grow as in-home patient services grows.

Show full opinionHide full opinion

They started to do Beta testing on this new software, then starting onboarding clients. The stock had ran up, then recently pulled back. Then, they ran into delays onboarding clients due to a hardware issue They should be back on track now. This will generate huge cash flow as they add subscribers; it will continue to grow as in-home patient services grows.

Showing 1 to 15 of 28 entries

Reliq Health Techniques(RHT-X) Rating

Ranking : 4 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 1

Stockchase rating for Reliq Health Techniques is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

Reliq Health Techniques(RHT-X) Frequently Asked Questions

What is Reliq Health Techniques stock symbol?

Reliq Health Techniques is a Canadian stock, trading under the symbol RHT-X on the TSX Venture Exchange (RHT-CV). It is usually referred to as TSXV:RHT or RHT-X

Is Reliq Health Techniques a buy or a sell?

In the last year, 1 stock analyst published opinions about RHT-X. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is TOP PICK. Read the latest stock experts' ratings for Reliq Health Techniques.

Is Reliq Health Techniques a good investment or a top pick?

Reliq Health Techniques was recommended as a Top Pick by Bruce Campbell (2) on 2021-09-02. Read the latest stock experts ratings for Reliq Health Techniques.

Why is Reliq Health Techniques stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is Reliq Health Techniques worth watching?

1 stock analyst on Stockchase covered Reliq Health Techniques In the last year. It is a trending stock that is worth watching.

What is Reliq Health Techniques stock price?

On 2021-09-20, Reliq Health Techniques (RHT-X) stock closed at a price of $0.83.